foto

Dr. A.G. Holleboom MD PhD

Position
Postdoc
Main activities
Patient care, Research
Specialisation
Endocrinology and Metabolism
Focus of research

Perturbed Lipid Pathways in Disorders of Protein Glycosylation and Golgi Trafficking

Key publications
  • Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, Herman DS, Stroes ESG, Aerts JM, Kastelein JJP, Motazacker MM, Dallinga-Thie GM, Levels JHM, Zwinderman AH, Seidman JG, Seidman CE, Ljunggren S, Lefeber DJ, Morava E, Wevers RA, Fritz TA, Tabak LA, Lindahl M, Hovingh GK, Kuivenhoven JA, Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. CELL METAB 2011;14 (6):811-818 [PubMed]
  • Holleboom AG, Daniil G, Fu X, Zhang R, Hovingh GK, Schimmel AW, Kastelein JJP, Stroes ESG, Witztum JL, Hutten BA, Tsimikas S, Hazen SL, Chroni A, Kuivenhoven JA, Lipid Oxidation in Carriers of Lecithin: Cholesterol Acyltransferase Gene Mutations. ARTERIOSCL THROM VAS 2012;32 (12):3066-+ [PubMed]
  • Holleboom AG, Jakulj L, Franssen R, Decaris J, Vergeer M, Koetsveld J, Luchoomun J, Glass A, Hellerstein MK, Kastelein JJP, Hovingh GK, Kuivenhoven JA, Groen AK, Turner SM, Stroes ESG, In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J LIPID RES 2013;54 (7):1964-1971 [PubMed]
  • Holleboom AG, Kuivenhoven JA, Peelman F, Schimmel AW, Peter J, Defesche JC, Kastelein JJP, Hovingh GK, Stroes ES, Motazacker MM, High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations. HUM MUTAT 2011;32 (11):1290-1298 [PubMed]
  • Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ, Kastelein JJP, Khaw KT, Boekholdt SM, Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J LIPID RES 2010;51 (2):416-421 [PubMed]
All Publications
Curriculum Vitae

In 2011, dr. Holleboom obtained his PhD in Mendelian disorders of HDL metabolism, funded by a TopTalent grant from the Netherlands Organisation of Scientific Research (NWO). As a resident in Internal Medicine in the Academic Medical Center at the University of Amsterdam, he focuses on endocrinology with a special interest for genetic metabolic and genetic lipid disorders. His research focuses on the role of protein glycosylation and Golgi trafficking in lipid metabolism, mainly by studies of lipid disorders in congenital disorders of protein glycosylation. He is supported by a Veni postdoctoral fellowship from the Netherlands Organisation for Scientific Research (ZonMW) and has appointed a PhD student at the University of Amsterdam. In 2014-2015, he joined the lab of dr. D.J. Rader, University of Pennsylvania Philadelphia, to perform translational studies within the mentioned research focus, applying both immortalized pluripotent stem cells as well as CRISPR Cas9 editing. His alliance with the Rader lab is supported by a grant from the Netherlands Foundation for Cardiovascular Excellence. 

Supervision of academic staff

PhD student Ms. M.A.W. van den Boogert MD

2015 Best abstract, Gordon Conference Glycobiology

2014 PhD AMC graduate school PhD scholarship (205.000)

2013 Outstanding Research by an Early Career Investigator award, Council Arteriosclerosis Thrombosis and Vascular Biology, American Heart Association Sessions, Dallas

MSc students (completed supervision and writing of thesis)

Mr. A. van der Made 2010-2011 (GALNT2 and ABCA1 studies), now intern in Medicine

Mr. J. Legemate 2010-2011 (GALNT2 and ABCA1 studies), now intern in Medicine

Mr. C. van Olden 2010 (familial LCAT deficiency), now intern in Medicine

 Research grants and awards

2015: Metakids foundation (e 30.000)

2013: Excellence3Award from the Netherlands Foundation for Cardiovascular Excellence (50.000)

2012: NWO (Netherlands Organization for Scientific Research)/ZonMw postdoctoral VENI grant (250.000) for Genetic defects in protein glycosylation as cause of dyslipidemia

2012: Netherlands Foundation for Cardiovascular Excellence, Nominee Excellence3 Award (1.000)

2012: AMC Graduate School Publication award (€ 700) for Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man (Cell Metabolism 2011).

2007: NWO TopTalent grant for doctoral research (€180.000) on atheroprotection by HDL through anti-inflammatory effects.

2006: Dr. I. Snapper Award for medical students from Amsterdam and Utrecht involved in internal medicine research, patient care and education (€ 2500)

Lectures and seminars

2013 - Gordon Research Conference Glycobiology, Ventura California

- Japanese Atherosclerosis Society Tokyo (lecture Established versus preliminary drug targets for dyslipidemia: lessons from LCAT deficiency syndromes versus congenital defects of protein glycosylation)

2015

-        Complex Carbohydrate Research Center, University of Georgia, Athens GA

-        Lipoprotein Section, NHLBI, NIH, Bethesda MD

Consult via MedaCorp concerning therapy development for LCAT deficiency    

 

 

 

Other research related activities
  • Contribution to training of professionals, University of Amsterdam
Current research funding
  • Amsterdam Gastroenterology and Metabolism Res. Institute
  • Radboud Universiteit Nijmegen
  • ZonMw